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Background: High serum carcinoembryonic antigen (CEA) levels are an independent prognostic factor for
recurrence and survival in patients with non-small cell lung cancer (NSCLC). Its role as a predictive marker of
treatment response has not been widely characterized.
Methods: 180 patients with advanced NSCLC (stage IIIB or Stage IV), who had an elevated CEA serum level
(>10 ng/ml) at baseline and who had no more than one previous chemotherapy regimen, were included. CEA
levels were measured after two treatment cycles of platinum based chemotherapy (93%) or a tyrosine kinase
inhibitor (7%). We assessed the change in serum CEA levels and the association with response measured by RECIST
criteria.
Results: After two chemotherapy cycles, the patients who achieved an objective response (OR, 28.3%) had a
reduction of CEA levels of 55.6% (95% CI 64.3-46.8) compared to its basal level, with an area under the ROC curve
(AURC) of 0.945 (95% CI 0.91-0.99), and a sensitivity and specificity of 90.2 and 89.9%, respectively, for a CEA
reduction of ≥14%. Patients that achieved a decrease in CEA levels ≥14% presented an overall response in 78% of
cases, stable disease in 20.3% and progression in 1.7%, while patients that did not attain a reduction ≥14% had an
overall response of 4.1%, stable disease of 63.6% and progression of 32.2% (p < 0.001). Patients with stable (49.4%)
and progressive disease (22.2%) had an increase of CEA levels of 9.4% (95% CI 1.5-17.3) and 87.5% (95% CI 60.9-114)
from baseline, respectively (p < 0.001). The AURC for progressive disease was 0.911 (95% CI 0.86-0.961), with
sensitivity and specificity of 85 and 15%, respectively, for a CEA increase of ≥18%. PFS was longer in patients with
a ≥14% reduction in CEA (8.7 vs. 5.1 months, p < 0.001). Reduction of CEA was not predictive of OS.
Conclusions: A CEA level reduction is a sensitive and specific marker of OR, as well as a sensitive indicator for
progression to chemotherapy in patients with advanced NSCLC who had an elevated CEA at baseline and had
received no more than one chemotherapy regimen. A 14% decrease in CEA levels is associated with a longer PFS.
Keywords: Carcinoembryonic antigen, Non small-cell lung cancer, Tumor markers, Prognosis, Response prediction* Correspondence: ogar@unam.mx
1Department of Medical Oncology, National Cancer Institute, Mexico City,
Mexico
2Laboratory of Experimental Oncology, National Cancer Institute, Mexico City,
Mexico
Full list of author information is available at the end of the article
© 2013 Arrieta et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Arrieta et al. BMC Cancer 2013, 13:254 Page 2 of 7
http://www.biomedcentral.com/1471-2407/13/254Background
Lung cancer is the most common cause of cancer-related
death in men and the second in women worldwide. It is
responsible for approximately 1.4 million deaths per year
[1]. Late diagnosis is common; more than 60% of patients
present with stage IIIB/IV disease [2]. In addition, more
than half of the remaining individuals treated with curative
intent will experience relapse, and eventually succumb
to their disease. The efficacy of chemotherapy (CT) in
advanced disease is limited; with responses ranging from 20
to 35%; and a 1-year survival rate of 35% [3,4]. Virtually, all
patients who initially respond will eventually progress.
Imaging studies remain the most objective available
tool to evaluate response to CT, and a response to CT is a
surrogate marker of clinical benefit, associated with a better
survival outcome [5]. In addition, several measurements
have been associated to response, such as changes or reduc-
tion of 18-fluorodeoxyglucose (FDG) metabolism evaluated
by positron emission tomography (PET). Nevertheless,
not all non-small-cell lung cancer (NSCLC) patients have
measurable disease; thus complicating the possibility of
evaluating objective responses. The value of serum markers
will always be especially useful for cases where the clinical
picture does not match the topographic measurements.
Regarding the use of markers as predictors of response to
treatment in several types of malignant tumors, there are
some antigens that have been proved useful. For example, in
advanced prostate and ovarian cancer, the roles of prostate-
specific antigen (PSA) and CA125, respectively, in predicting
response to treatment and survival outcome have been
clearly established and these markers are used routinely in
clinical practice to monitor the effects of therapy [6].
The carcinoembryonic antigen (CEA) is an important
marker for malignant tumors, including NSCLC. High
serum CEA levels have been identified as a prognostic
factor in both resected NSCLC [7-14] and metastatic
disease [15,16]. However, the role of CEA as a predictive
marker of response to CT has not been widely evaluated.
The objective of this study was to assess in a prospective
manner both the sensitivity and the specificity of the
changes in CEA levels and their relationship to response
to CT treatment; as well as their association to progression




Approval for this study was obtained from the Institutional
Ethics Committee (010/059/ICI)(CB/675). Patients with
the diagnosis of NSCLC treated at the National Cancer
Institute of Mexico were recruited between February 2009
and May 2010. Inclusion criteria comprised: histologically
proven diagnosis of NSCLC, patients with unresectable or
metastatic disease, measurable disease, Eastern CooperativeOncology Group (ECOG) performance status 0–2, life
expectancy > 3 months, and patients cadidates for pal-
liative first or second line CT. Patients with personal
history of previous malignant neoplasms were excluded.
Tumor assessment by computed tomography was made
at baseline and after two chemotherapy cycles. Only
patients with CEA baseline levels > 10 ng/mL were in-
cluded. Treatment consisted of a doublet platinum-based
chemotherapy scheme or a tyrosine-kinase inhibitor (TKI).
Initial response was determined by tomography using the
established RECIST criteria [17].
Demographic data, medical history, and physical examin-
ation were performed before study entry. Height, weight,
vital signs, ECOG performance status, and vital signs were
assessed at every medical visit. CEA levels were measured
at study entry before starting CT treatment and at the
time of tomographic evaluation. Patients were followed
until progression, death or last medical visit.
CEA determination and analysis
Peripheral blood samples were obtained on day 1 before
CT and after two CT cycles. Measurement was performed
at the Clinical Pathology Laboratory of the National Cancer
Institute of Mexico using a sequential chemoluminiscent
immunoassay (Immulite 2000).
Statistical analysis
With a descriptive purpose, we resumed continuous
variables as arithmetic means, medians and standard
deviations and categorical variables as proportions with
95% confidence intervals (95% CI’s). Sensitivity and speci-
ficity were calculated for the CEA levels and response
measured by tomography. The association between CEA
levels with overall response was calculated with Xi square
test. Receiver operating characteristics (ROC) curve ana-
lysis to determine the best cut-off value for CEA levels to
achieve a 90% specificity was undertaken. PFS was defined
as the time-period from date of beginning of treatment to
date of progressive disease by confirmed image or last
follow-up, and OS was defined as the time-period from
histological diagnosis to date of death or last follow-up
visit. Survival was analyzed with the Kaplan-Meier method,
and subgroups were compared with the log-rank and
Breslow test. Statistical significance was determined with a
p ≤ 0.05 in a two-sided test.
Results
Between February 2009 and May 2010, a total of 426 pa-
tients with the diagnosis of advanced NSCLC were screened
for CEA levels before the start of CT. One-hundred eighty
patients (42%) with an abnormal baseline CEA level
(>10 ng/mL) were prospectively recruited with a mean
baseline CEA of 242.8 ng/mL (range, 10–7,440 ng/mL).
Fifty-four percent were men and 46% were women
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were smokers (57%) and seventy-three (41%) had wood-
smoke exposure. Regarding histology, adenocarcinoma was
the most common, being present in 152 patients (84%), as
previously shown in our previous report [16]. In our study,
CEA levels were lower in the non-adenocarcinoma hist-
ology group subtype compared to the adenocarcin-
oma, although this was not significantly different
(128.9 vs. 264.3 ng/dl, p = 0.881). From the 180 patients
with elevated CEA levels, 93.3% (168 patients) received a
platinum-based chemotherapy, while 6.7% (12 patients)
received a TKI (Table 1).
Objective response (complete plus partial response, OR),
stable disease (SD) and progressive disease (PD) were
28.3, 49.4 and 22.2% respectively. Patients with OR had a
CEA level reduction of 55.6% (95% CI 64.3-46.8); while
patients with SD and PD had an increase of 9.4% (95%
CI 1.5 to 17.3) and 87.5% (95% CI 60.9 to 114), respect-
ively (p < 0.001).
The ROC curve analysis for the changes in CEA levels
in responsive patients had an area under the curve (AUC)Table 1 Baseline patient and tumor characteristics
N = 180 Mean ± SD Patients n (%)























Large-cell carcinoma 1 (0.6)
Baseline CEA 242.8 ± 685
Treatment







Stable Disease 89 (49.4)
Progressive Disease 40 (22.2)
Abbreviations: SD, standard deviation; CEA, carcinoembryonic antigen; CT,
chemotherapy.of 0.945 (95% CI 0.91 to 0.99; Figure 1A). Sensitivity and
specificity were of 90.2 and 89.9%, respectively for a CEA
level reduction of 14% or greater. Patients that achieved a
decrease in CEA levels ≥14% presented an overall response
in 78% of cases, stable disease in 20.3% and progression in
1.7%, while patients that did not attain a reduction ≥14%
had an overall response of 4.1%, stable disease of 63.6%
and progression of 32.2% (p < 0.001). When we analyzed
the CEA level decline associated with tumor response
specifically in patients with non-adenocarcinoma, we
found that patients with a reduction of ≥14%, had an
overall response of 66.7%, stable disease 16.7%, and pro-
gression 16.7%, compared to the non-adenocarcinomaArea under the curve 
0.945 (95 CI% 0.906-0.985) 
Area under the curve 
0.911 (95 CI% 0.86-0.961) 
B
Figure 1 Correlation between CAE levels and response. A. ROC
curve for CEA levels and overall response. B. ROC curve for CEA
levels and progressive disease.
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a tumor response of 9.1%, 59.1% and 31.8%, respectively
(p = 0.009).
Although the number of evaluated patients treated
with EGFR-tyrosine kinase was limited (12 patients),
patients with reduction in CEA levels ≥14%, had an
overall response of 100%, compared to patients that
did not have a CEA level reduction who achieved an overall
response in 0%, stable disease in 70%, and progressive
disease in 30% (p = 0.002).
The AUC in progressive disease was 0.911 (95% CI 0.86
to 0.96; Figure 1B), with a sensitivity and specificity of 85
and 15%, respectively, for a CEA level increase of 18%
from baseline.
Median follow-up time was of 11.8 ± 8.4 months.
According to RECIST criteria, patients that achieved
OR had a superior PFS compared to patients with
stable or progressive disease (Figure 2A). Similarly,
PFS was longer in patients with a ≥14% reduction in
CEA (8.7 months [CI 95% 8.4 to 9.0] vs. 5.1 months
[CI 95% 4.5 to 5.8], p < 0.001; Figure 2B). Neither reduction
of CEA (p = 0.48) nor OR measured by RECIST (p = 0.28)
were predictive of OS.
Discussion
CEA is a glycoprotein product of the gene CEACAM-5.
It is a member of the immunoglobulin super family that
serves as a cell-adhesion molecule and may also play a
role in innate immunity [18]. CEA is often overexpressed
in many malignant neoplasms including NSCLC and is
readily detected in serum samples making it a valuable
tool for the follow-up and prognosis of patients.
The role of CEA as a prognostic factor has been well
established in colon cancer and is now part of the routine
follow-up evaluation recommended by the current NCCN
guidelines [19-22]. Moreover, Iwanicki et al. showed that
the CEA kinetic allowed accurate evaluation of progression,
response, and PFS in metastatic colon cancer suggesting an
important role in objective response assessment [23]. In
NSCLC, many studies evaluating CEA and prognosis have
been written with contrasting results in the perioperative
setting, some showing its role as a prognostic value
[8,10,13,24] and others not confirming it [25-27].
The method for assessing treatment response in cancer
patients is through the change in tumor size measured by
computed tomography [17]. Though objective and well
validated, it has inadequacies in daily practice settings as
in the case of patients with pleural effusions, diffuse
nodules, or tumors with poorly defined margins. Erasmus
et al [28]. demonstrated that these measurements are
often inconsistent and can lead to incorrect interpretation
of tumor response; thus mandating for novel strategies in
response evaluation. It would be especially useful to have
a serum marker that can correlate with response in thisparticular setting. In addition, for advanced patients who
are submitted to multiple imaging studies for follow-up
and monitoring of progression, the assessment of a par-
ticular serum marker can obviate more time-consuming
and expensive imaging evaluations, and can guide the
clinician on the timing to request further studies when its
elevation suggests progression. In this regard, five recent
studies have reported that in NSCLC patients, the CEA
levels can correlate with response to treatment.
A recent retrospective report by Ishiguro et al. [29] of
24 Japanese patients with resectable NSCLC showed a
significant decrease of serum CEA levels after neoadjuvant
chemotherapy in patients achieving partial response. They
found a 60% reduction of CEA levels as an appropriate
cutoff value for good response by ROC curve analysis; at
this set-point, they found a sensitivity of 82.8% and a
specificity of 69.2% for achieving objective response.
The prognostic and predictive value of pretreatment
serum levels of CEA have been assessed in advanced
NSCLC patients exclusively treated with gefitinib and
erlotinib and, owing that conflicting results have been
reported a direct relationship between high levels of CEA
and response to EGFR-TKI, however its utility has not
yet been established. Chiu et al. [30] and Xu et al. [31]
assessed the clinical value of CEA in prediction of EGFR-
TKI therapy response in advanced NSCLC patients. The
former authors found an association between image re-
sponse and tumor marker assessment at 4 weeks of ther-
apy. Unexpectedly, they found no association between
CEA and PFS nor OS. The latter authors assessed CEA
levels at baseline and after 4 weeks of an EGRF-TKI in ad-
vanced NSCLC patients; they found that a decrease of
≥32% from baseline was closely related to OR and a longer
median survival time, which confirms our findings. In the
other hand, Okamoto et al [32] and Jung et al [33]
reported that patients treated with EGFR-TKI with high
pretreatment levels of CEA had a longer survival and a
better response than those with low CEA levels.
Ardizzoni et al. [15] explored the value of CEA in
advanced NSCLC patients receiving platinum-based CT.
They found that a reduction of ≥20% of CEA after 2 cycles
of CT had accuracy for predicting response by ROC curve
analysis of 0.65, with a sensitivity of 55% and a specificity
of 75%. They also found a difference regarding histology
subtype, showing a significant association between
adenocarcinoma OR by RECIST and CEA-response
which was only barely significant with the squamous
histology. Additionally, they did find a relation between
marker response and OS. Jin et al. [34] also assessed the
value of CEA in response prediction in advanced NSCLC
receiving platinum-based CT. They reported a significant
association between the change in CEA and OR, time-to
progression and OS; they did not, however, evaluated the
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Figure 2 Progression free survival in patients who have radiological response and CEA level reduction. A. Kaplan-Meier curve comparing
PFS in overall response vs stable/progressive disease. B. Kaplan-Meier curve comparing PFS in patients with a ≥ 14% reduction of CEA levels.
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sensitivity and specificity.
In our study with advanced NSCLC patients receiving
platinum-based CT and TKI therapy (in a small subset
of patients), we corroborated the findings of previous
investigators on the usefulness of CEA in predicting
response to treatment in a prospective fashion and, to
our knowledge, this is the largest cohort of patients in
which the role of CEA as a predictive tool is validated.
Using a set point of ≥14% reduction of CEA levels after
two cycles of treatment, we managed to increase the
accuracy for response prediction by ROC curve analysis(AURC, 0.94), and to increase the sensitivity and specificity
of the marker for OR prediction. Likewise, we found that
an increase of CEA values after two cycles ≥18% also corre-
lated well with PD with a sensitivity of 85%. Additionally,
when CEA changes were evaluated according to histology,
not only adenocarcinoma patients showed a difference
in tumor response, but these changes were also noted
in non-adenocarcinoma patients.
We described a significant association between the
reduction of CEA and PFS but not OS, interestingly, OR by
standard RECIST technique also did not show significance
for OS. We postulate that the reason that the CEA
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that in this cohort of patients, most of them received
further treatment with 2 to 4 lines of chemotherapy
and/or tyrosine kinase inhibitors.
Perhaps the better performance of CEA in our
study is due to the high representation of patients
with adenocarcinoma (84%) in a large cohort. It
has previously been demonstrated that CEA levels
correlate more accurately to prediction of prognosis
and OR in adenocarcinoma histology than non-
adenocarcinoma [15,35]. Matsuoka et al. [7] showed a
relationship between histologic subtype and the usefulness
of CEA as a prognostic indicator in NSCLC patients with
pathologic stage I, showing that a high preoperative CEA
level was associated to shorter disease-free survival and
lower 5-year survival rate in adenocarcinoma compared to
the squamous histology in whom it was not predictive
of survival nor recurrence. Furthermore, a report by
Reinmuth et al. [27] evaluating the prognostic impact of
CEA in resectable NSCLC patients failed to reach sta-
tistical significance, importantly, they had an over-
representation of patients with squamous-cell carcinoma
(46% overall).
In this study, we confirmed that CEA measurements
during follow-up are particularly helpful in patients with
elevated CEA at diagnosis with measurable disease,
although they might be potentially useful for unmeas-
urable disease as well, such as pleural effusions, diffuse
nodules, or tumors with poorly defined margins, according
to a previously published study [30].
The usefulness of other tumor markers than CEA has
been evaluated in resectable and advanced NSCLC. Of
note, the immunometric assay of cytokeratin-19 fragments
(CYFRA 21–1) has been the most studied yielding
great results as a prognostic [36,37] and OR-predictive
tool [15,34,35]. We chose to use only CEA because of its
wider availability for routine clinical use and standardized
performance.Conclusions
A ≥14% reduction of serum CEA level from baseline
after 2 cycles of treatment in advanced NSCLC is an ac-
curate measurement of OR compared to RECIST, it has
outstanding sensitivity and specificity, and correlates
well with PFS especially in adenocarcinoma histology.
Contrariwise, an increase of ≥18% of serum CEA levels
from baseline is also an accurate measurement of PD.
Together with the two previous studies, we demon-
strated the predictive value of measuring CEA levels in
NSCLC and we propose it to be part of the routine
follow-up of advanced NSCLC patients who have
increase levels of CEA (>10 mg/dl) at baseline and are
receiving platinum-based CT.Clinical practice points
 Declining CEA levels have been studied in advanced
NSCLC patients with similar results [15,30-32],
although, with a smaller cohort of patients and a
significant underrepresentation of adenocarcinoma
histology [27] in which CEA measurement is most
useful.
 In the surgical setting, Matsuoka et al. [33] proved
that CEA declining levels are valuable as a
prognostic marker of recurrence, also in the
adenocarcinoma subtype.
 A decrease of ≥14% of serum CEA level from
baseline had 90% specificity for overall tumor
response making it a promising tool and a more
objective method of evaluating response to
chemotherapy in advanced NSCLC patients.
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